Compare Crispr Therapeutics AG (CRSP) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs VNET Group Inc — how do they compare? Crispr Therapeutics AG trades at $50.91 (market cap $4.97B), while VNET Group Inc trades at $7.79 (market cap $2.21B). The key difference: Crispr Therapeutics AG is far larger — about 2.2× VNET Group Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | VNET | |
|---|---|---|
Market Cap | $4.97B | $2.21B |
Sector | Health | Technology |
52-Week High | $76.78 | $14.03 |
52-Week Low | $44.34 | $7.34 |
Enterprise Value | $3.32B | $5.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
VNET Group trades at $7.72, down 3.62% on the day, with a bearish technical signal and negative earnings momentum after missing Q1 2026 EPS estimates. The company reported a net loss of $256.77 million in 2025, with profitability metrics like ROE at -43.21% indicating financial strain. However, revenue grew to $9.95 billion, and analyst sentiment remains largely positive with a 62.5% buy rating, citing AI-driven demand and new strategic investments from entities linked to CATL.
The outlook is mixed: strong revenue growth and strategic positioning in data centers offer upside, but persistent losses and high debt pose significant risks. Investors should weigh the potential from AI expansion against execution challenges and financial health concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
